A pilot clinical trial of cell therapy in heart failure with preserved ejection fraction

Vrtovec, Bojan; Frljak, Sabina; Poglajen, Gregor; Zemljic, Gregor; Cerar, Anton; Sever, Matjaž; Haddad, François; Wu, Joseph C.

doi:10.1002/ejhf.2596

Cited by 4 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD34+ cell therapy was associated with improvements in E/e' (primary endpoint), N-terminal pro-B-type natriuretic peptide, exercise capacity, and local myocardial strain at the cell injection sites, compared with pre-implantation values. 27…”

Section: Novel Optionsmentioning

confidence: 99%

“…The effects of CD34+ transendocardial cell therapy have been assessed in a prospective non‐randomized pilot study enrolling 30 HFpEF patients who underwent cell transplantation and were followed for 6 months. CD34+ cell therapy was associated with improvements in E/e' (primary endpoint), N‐terminal pro‐B‐type natriuretic peptide, exercise capacity, and local myocardial strain at the cell injection sites, compared with pre‐implantation values 27 …”

Section: Heart Failure With Preserved Ejection Fractionmentioning

confidence: 99%

See 1 more Smart Citation

August 2022 at a glance: focus on heart failure with preserved ejection fraction and cardiac amyloidosis

Tomasoni

Adamo

Metra

2022

European J of Heart Fail

View full text Add to dashboard Cite

Section: Novel Optionsmentioning

confidence: 99%

Section: Heart Failure With Preserved Ejection Fractionmentioning

confidence: 99%

August 2022 at a glance: focus on heart failure with preserved ejection fraction and cardiac amyloidosis

Tomasoni

Adamo

Metra

2022

European J of Heart Fail

View full text Add to dashboard Cite

“…They then received therapy with CD34+ cells administered transendocardially in a second phase. After a follow-up period of 6 months, they found that CD34+ cell transplantation is feasible and safe and was associated with favorable results based on the measurement of E/e' ratio, NT-proBNP levels, and the distance walked in the 6 min walk test (6 MWT) [162].…”

Section: Cell Therapy and The Futurementioning

confidence: 99%

New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back

et al. 2022

View full text Add to dashboard Cite

Heart failure with preserved ejection fraction (HFpEF) is a growing public health problem in nearly 50% of patients with heart failure. Therefore, research on new strategies for its diagnosis and management has become imperative in recent years. Few drugs have successfully improved clinical outcomes in this population. Therefore, numerous attempts are being made to find new pharmacological interventions that target the main mechanisms responsible for this disease. In recent years, pathological mechanisms such as cardiac fibrosis and inflammation, alterations in calcium handling, NO pathway disturbance, and neurohumoral or mechanic impairment have been evaluated as new pharmacological targets showing promising results in preliminary studies. This review aims to analyze the new strategies and mechanical devices, along with their initial results in pre-clinical and different phases of ongoing clinical trials for HFpEF patients. Understanding new mechanisms to generate interventions will allow us to create methods to prevent the adverse outcomes of this silent pandemic.

show abstract

The origin, progress, and application of cell‐based cardiac regeneration therapy

Zhuo

Lei

et al. 2023

Journal Cellular Physiology

View full text Add to dashboard Cite

Cardiovascular disease (CVD) has become a severe threat to human health, with morbidity and mortality increasing yearly and gradually becoming younger. When the disease progresses to the middle and late stages, the loss of a large number of cardiomyocytes is irreparable to the body itself, and clinical drug therapy and mechanical support therapy cannot reverse the development of the disease. To explore the source of regenerated myocardium in model animals with the ability of heart regeneration through lineage tracing and other methods, and develop a new alternative therapy for CVDs, namely cell therapy. It directly compensates for cardiomyocyte proliferation through adult stem cell differentiation or cell reprogramming, which indirectly promotes cardiomyocyte proliferation through non‐cardiomyocyte paracrine, to play a role in heart repair and regeneration. This review comprehensively summarizes the origin of newly generated cardiomyocytes, the research progress of cardiac regeneration based on cell therapy, the opportunity and development of cardiac regeneration in the context of bioengineering, and the clinical application of cell therapy in ischemic diseases.

show abstract

A pilot clinical trial of cell therapy in heart failure with preserved ejection fraction

Abstract: We investigated the effects of CD34 + cell therapy in patients with heart failure with preserved ejection fraction (HFpEF).

Cited by 4 publications

References 31 publications

August 2022 at a glance: focus on heart failure with preserved ejection fraction and cardiac amyloidosis

August 2022 at a glance: focus on heart failure with preserved ejection fraction and cardiac amyloidosis

New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back

The origin, progress, and application of cell‐based cardiac regeneration therapy

Contact Info

Product

Resources

About